CE Concepts
@CE_Concepts
Live & enduring accredited activities for physicians (#ACCME), nurses (#ANCC), pharmacists (#ACPE), and related members of the health care team (#IPCE)
📊 Cutting-edge therapies for HR+/HER2- mBC! Join Dr. Sara Tolaney as she unpacks clinical trial data & real-world insights on ADC therapies. Participate Now: ce.ceconcepts.com/BC-119 #Oncology #BreastCancer #ADCTherapies
WATCH NOW: Grand Rounds on Advancing Cervical Cancer Care:New Therapies, Guidelines Credit Info: ce.ceconcepts.com/GRV084encore x.com/i/broadcasts/1…
📖 Guidelines, consensus, and patient care for HR+/HER2- mBC! Join Dr. Sara Tolaney as she dives into ADC therapies and practice-changing strategies in this BriefCase. Participate Now: ce.ceconcepts.com/BC-120 #Oncology #BreastCancer #ADCTherapies
WATCH NOW: MEK Inhibitors in NF1-PN: Advances & Applications. Resources+credit: ce.ceconcepts.com/MMV154encore x.com/i/broadcasts/1…
WATCH NOW: Grand Rounds Discussion on Advancing Cervical Cancer Care. Get credit: ce.ceconcepts.com/GR086credit x.com/i/broadcasts/1…
🌟Check out our sister company @CMEOutfitters' video: Exploring a patient case through the lens of clinical practice with Dr. Luna and their pronouns. Dive into the complexities of #mentalhealth assessment & treatment in this insightful discussion. #MentalHealthAwareness
ICYM @CMEOfitters' video on: Optimizing treatment plans is crucial, especially when faced with challenges. Thinking outside the box and considering new options like a glutamate-based NMDA treatment could be a game-changer. #healthcare #treatmentoptions #continuouslearning
🌟 Exploring antibody-drug conjugates in HR+/HER2- metastatic breast cancer! Dr. Sara Tolaney brings real-world cases and clinical trial data to life in this BriefCase. Ready to enhance your oncology expertise? Participate now: ce.ceconcepts.com/BC-119 #OncologyEducation…
WATCH NOW! Emerging Considerations: Biomarker-Driven Immunotherapy in Upper GI Cancers. Hosted by Drs. Klempner, Swanson and Cytryn. Download the resources + credit info here: ce.ceconcepts.com/WC102CG x.com/i/broadcasts/1…
🌟 Understanding and managing adverse events (AEs) in ADC therapy is critical for improving quality of life in patients with HR+/HER2- metastatic breast cancer. In this BriefCase, Julie LaBarbera and Dr. Sonya Reid share real-world strategies to monitor and manage AEs…
Staying ahead in oncology means integrating the latest guidelines, expert consensus, and emerging data into your practice. In this BriefCase, Dr. Sara Tolaney explores how to incorporate antibody-drug conjugates (ADCs) into treatment plans for HR+/HER2- metastatic breast cancer.…
🌈 Amplify LGBTQ+ patient voices this Pride Month! 🌈 Embracing diversity and inclusion, we understand the significance of LGBTQ+ healthcare representation. Together, we can make a difference and ensure every patient receives compassionate and inclusive healthcare.…
🎯 Managing ADC-related AEs in HR+/HER2- mBC is key to improving QoL. Join Julie LaBarbera and Dr. Sonya Reid as they explore monitoring & management strategies in this BriefCase: ce.ceconcepts.com/BC-121 #Oncology #BreastCancer #ADCTherapies
📊 Cutting-edge therapies for HR+/HER2- mBC! Join Dr. Sara Tolaney as she unpacks clinical trial data & real-world insights on ADC therapies. Participate Now: ce.ceconcepts.com/BC-119 #Oncology #BreastCancer #ADCTherapies
📖 Guidelines, consensus, and patient care for HR+/HER2- mBC! Join Dr. Sara Tolaney as she dives into ADC therapies and practice-changing strategies in this BriefCase. Participate Now: ce.ceconcepts.com/BC-120 #Oncology #BreastCancer #ADCTherapies
Thank You for Attending! 🙌 A huge THANK YOU to all the HCPs & oncology experts who joined us LIVE for today’s CEC Oncology symposium on NF1-PN management & MEK inhibitors! 💡 Missed the session? Stay tuned—we’ll share key takeaways soon! ➡️ What was your #1 takeaway from…
WATCH NOW: MEK Inhibitors in Neurofibromatosis Type 1 Hosted by @AngelaHirbe and Amy Armstrong, MD Resources + credit info»ce.ceconcepts.com/MMS153CG. #MedTwitter #MedEd #FOAMed #NF x.com/i/broadcasts/1…
🔴STARTING IN 15 MINUTES MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-world Applications in NF1-PN Management 🥼 @AngelaHirbe @armstrong_ae 📍 Kentucky International Convention Center | Room: Ballroom B | Louisville, KY 🔗 ce.ceconcepts.com/MM-153…
We’re Live in 1 hour—Join Us! 🔴 We’re officially LIVE here at CEC Oncology—tune in now to explore how MEK inhibitors are changing the game for NF1-PN treatment! 🥼 @AngelaHirbe @armstrong_ae 📍 Kentucky International Convention Center | Room: Ballroom B | Louisville, KY 🔗…
Final Call—TOMORROW! ⏳LIVE MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-world Applications in NF1-PN Management 🎤 What’s in store? ✅ How to identify early signs of NF1 ✅ Latest MEK inhibitor data & treatment strategies ✅ Practical case discussions…